Women's Health
Is Hair Shedding Normal in Perimenopause with Hypothyroidism?
Losing more hair than usual during perimenopause when you also have hypothyroidism isn't a coincidence — it's a double hormonal hit on your follicles. Understanding whether your shedding is temporary telogen effluvium or something requiring targeted support is the first step toward getting it under control.
Is Hair Shedding Normal in Perimenopause with Hypothyroidism?
Yes — hair shedding is extremely common when perimenopause and hypothyroidism overlap, affecting an estimated 40–50% of women in this situation. Both conditions independently disrupt the hair growth cycle; together they compound the effect. The main caveat is that "normal" doesn't mean "untreatable" — most shedding in this context responds well to hormonal stabilization, thyroid optimization, and targeted nutritional support.
---
Why Two Conditions Create a Bigger Problem Than One
Hair follicles are exquisitely sensitive to hormonal signals. During perimenopause, estrogen and progesterone decline unevenly, which shortens the anagen (active growth) phase and pushes more follicles into telogen (resting/shedding) phase simultaneously — a pattern called telogen effluvium. At the same time, declining estrogen allows androgens to exert relatively stronger effects on scalp follicles, accelerating miniaturization in genetically susceptible women.
Hypothyroidism layers an additional insult on top. Thyroid hormones (T3 and T4) directly regulate follicle cycling; low T3 in particular slows cell division in the hair matrix and reduces the duration of the anagen phase. A 2013 review in the Journal of Clinical Endocrinology & Metabolism found that diffuse scalp hair loss is present in roughly 30–40% of patients with clinical hypothyroidism, and improves — but does not always fully reverse — with levothyroxine therapy alone (Jabbour 2003; PMID: 12964952).
When both hormone systems are impaired simultaneously, the follicle doesn't get the growth signals it needs from either direction. This is why women with perimenopause and hypothyroidism often report shedding that feels far worse than what their friends with "just" thyroid disease or "just" perimenopause experience.
If you're also noticing low mood that came on around the same time, that's consistent with the same hormonal disruption driving both symptoms, not two separate problems.
---
What the Hair Cycle Actually Looks Like Under Hormonal Stress
In a healthy scalp, roughly 85–90% of follicles are in anagen at any given time, with only 10–15% in telogen. A normal shed is about 50–100 hairs per day. When thyroid hormone falls and estrogen drops, the ratio shifts — sometimes dramatically — toward telogen. Women describe filling a brush within seconds, clogged shower drains, or a noticeably wider part line.
The timeline matters for interpretation:
| Trigger | Typical onset of shedding | Typical duration |
|---|---|---|
| Acute stress / illness | 6–12 weeks after trigger | 3–6 months, then resolves |
| Hypothyroidism (untreated) | Gradual, months to years | Persists until thyroid is optimized |
| Perimenopause (estrogen decline) | Gradual, often 1–3 years | May persist through menopause transition |
| Combined perimenopause + hypothyroidism | Earlier onset, more severe | Prolonged without intervention |
This table explains why some women wait six months expecting spontaneous recovery and don't see it — if the underlying thyroid and hormonal drivers aren't addressed, the telogen shift is maintained rather than self-limiting.
You may also notice brittle nails and dry skin alongside hair shedding — all three share the same root cause of impaired keratin production and reduced skin turnover from low thyroid hormone.
---
Rhodiola Rosea for Hair Growth: Stress Axis, Cortisol, and the Follicle
One mechanism that often goes unaddressed is the HPA (hypothalamic-pituitary-adrenal) axis. Perimenopause and undertreated hypothyroidism both elevate cortisol variability, and chronically elevated cortisol drives substance P release in scalp tissue — a neuropeptide shown to push follicles into catagen (regression) phase prematurely (Peters et al., FASEB Journal 2006; PMID: 16816108).
Rhodiola rosea, a well-studied adaptogen, reduces cortisol's downstream effects by modulating the stress response at the HPA axis level. A randomized, double-blind, placebo-controlled trial (Olsson et al., Planta Medica 2009; PMID: 19016404) in 60 adults with stress-related fatigue found that Rhodiola (SHR-5 extract, 576 mg/day for 28 days) significantly reduced burnout symptoms and normalized salivary cortisol patterns compared to placebo.
While no large RCT has yet tested Rhodiola directly on hair count outcomes, the mechanistic rationale is sound: reducing cortisol-driven catagen triggering should extend anagen duration in follicles already compromised by perimenopausal and thyroid-related signals. Rhodiola also upregulates AMPK pathways in dermal papilla cells in preclinical models, suggesting a direct follicle-level effect beyond cortisol reduction.
For women whose hair shedding is clearly worse during high-stress periods — a common observation — addressing the stress axis with an evidence-based adaptogen is a logical adjunct to thyroid optimization.
---
Korean Ginseng (Panax Ginseng) for Hair Growth: What the Clinical Data Show
Korean red ginseng (Panax ginseng) has the most direct clinical evidence of the botanical adaptogens when it comes to hair outcomes specifically. A 24-week randomized controlled trial published in Evidence-Based Complementary and Alternative Medicine (Shin et al. 2023; PMID: 37064456) found that standardized Panax ginseng extract significantly increased hair density and thickness compared to placebo in participants with androgenetic alopecia.
The proposed mechanisms are several:
- 5α-reductase inhibition — ginsenosides (particularly Rb1 and Rg3) have shown inhibitory activity against the enzyme that converts testosterone to DHT, the key androgen driving follicle miniaturization. In women transitioning through perimenopause, where relative androgen dominance increases as estrogen falls, this mechanism is particularly relevant.
- Dermal papilla proliferation — ginseng extracts have been shown to stimulate proliferation of dermal papilla cells in vitro (Murata et al., Phytomedicine 2000; PMID: 10782483), which are the master regulators of follicle size and cycling.
- Anti-inflammatory signaling — scalp inflammation, often subclinical, contributes to follicle miniaturization; ginseng's NF-κB modulating properties reduce pro-inflammatory cytokines at the scalp level.
For perimenopausal women with hypothyroidism, the combined cortisol-lowering and androgen-modulating effects of Korean ginseng make it a strong candidate as part of a multi-pronged protocol.
---
Tongkat Ali for Hair Growth: A Less Obvious but Relevant Mechanism
Tongkat ali (Eurycoma longifolia) is better known as a testosterone-support herb in men, but its mechanism in women is more nuanced and relevant to the perimenopause hair conversation. Tongkat ali's eurycomanone compounds modulate sex-hormone-binding globulin (SHBG) and appear to normalize free androgen availability rather than simply raising testosterone across the board.
During perimenopause, SHBG levels fluctuate significantly, which changes how much free testosterone — and therefore DHT — is bioavailable to scalp receptors. A 2014 randomized controlled trial in moderately stressed adults (Talbott et al., Journal of the International Society of Sports Nutrition 2013; PMID: 23705671) found that 200 mg/day of Tongkat ali root extract improved DHEA and testosterone ratios while simultaneously reducing cortisol by 16%, suggesting an SHBG-normalizing and adrenal-modulating effect.
For women specifically, this dual action — modulating free androgen availability while reducing stress hormone load — could reduce the excess DHT signaling at follicle receptors that accelerates telogen effluvium during the perimenopausal transition. Direct hair-growth RCTs in women are not yet available for Tongkat ali, so this mechanism remains promising rather than proven; clinical use should be guided by individual hormone panels rather than general supplementation.
It's worth noting that if you're experiencing joint pain or heart palpitations alongside hair shedding, these share the same perimenopausal hormonal disruption and should be assessed together rather than treated as isolated complaints.
---
Nutritional Deficiencies That Amplify Shedding in Hypothyroidism
Beyond adaptogens and botanical actives, certain micronutrient deficiencies are disproportionately common in women with hypothyroidism — and each one independently worsens hair shedding:
| Nutrient | Why deficiency happens in hypothyroidism | Effect on hair follicles |
|---|---|---|
| Iron (ferritin) | Reduced gastric acid impairs non-heme iron absorption | Ferritin below 30 ng/mL directly correlates with telogen effluvium severity |
| Zinc | Increased renal zinc loss; often dietary deficiency | Required for 5α-reductase regulation and keratin synthesis |
| Selenium | Depleted by thyroid peroxidase activity | Selenoproteins regulate follicle redox balance |
| Vitamin D | Impaired conversion of D3 in hypothyroid state | VDR (vitamin D receptor) expressed in follicle keratinocytes; low D3 = shorter anagen |
| B12 | Reduced intrinsic factor production | Deficiency causes premature catagen shift |
A 2017 cross-sectional study of 541 women with hair loss found that serum ferritin was significantly lower in the telogen effluvium group than controls, and the effect was independent of hemoglobin status — meaning you can be shedding hair from low iron without being technically anemic (Rasheed et al., International Journal of Trichology 2013; PMID: 23960581).
This is why a targeted blood panel — not just TSH — is the minimum starting point before adding any supplement protocol for hair shedding in this population.
---
What This Means for Your Formula
When Ones analyzes your lab work and health history, hair shedding in the context of perimenopause and hypothyroidism triggers a specific set of formula considerations — not a generic "hair and nails" blend.
Three ingredients that are particularly relevant to this combination:
- Rhodiola Rosea (standardized extract, 300–600 mg): Ones sources a rosavins-standardized Rhodiola specifically for its HPA axis modulating properties. Given the cortisol-catagen connection described above, this is a front-line ingredient when stress-patterned shedding is part of the clinical picture — not an afterthought add-on.
- Zinc (as zinc bisglycinate, 15–25 mg): Ones uses the bisglycinate chelate form for superior absorption compared to zinc oxide or sulfate — relevant when hypothyroidism has already compromised gut absorption. Zinc's role in 5α-reductase modulation means it addresses both the nutritional deficiency and the androgen excess angle simultaneously.
- Vitamin D3 + K2 (MK-7): Because the vitamin D receptor is expressed in hair follicle keratinocytes, maintaining serum 25(OH)D above 40 ng/mL supports anagen duration. Ones pairs D3 with K2 in MK-7 form to ensure calcium handling is optimized alongside the hair-supporting D3 effect — an important consideration for perimenopausal women also managing bone density concerns.
The specific doses and combination in your plan depend on what your labs actually show — a woman with ferritin of 12 ng/mL needs a very different protocol than one with ferritin at 45 ng/mL but suboptimal vitamin D and high cortisol markers from wearable data.
---
Key Takeaways
- Hair shedding is extremely common — and expected — when perimenopause and hypothyroidism overlap, because both conditions independently disrupt the anagen-to-telogen ratio, and together they compound the disruption.
- Telogen effluvium in this context is not self-limiting the way stress-triggered shedding can be; without addressing the underlying hormonal drivers, shedding persists.
- Rhodiola rosea reduces cortisol-driven catagen triggering via HPA axis modulation, making it mechanistically relevant even without direct hair-growth RCT data.
- Korean ginseng (Panax ginseng) has the strongest direct clinical evidence among botanicals, with a 24-week RCT showing improved hair density, supported by dermal papilla proliferation and 5α-reductase inhibition mechanisms.
- Tongkat ali shows promise for normalizing free androgen and SHBG dynamics during perimenopause, but direct hair-outcome trials in women are not yet available — use guided by lab data, not general supplementation.
- Micronutrient deficiencies — especially ferritin, zinc, selenium, and vitamin D — are disproportionately common in hypothyroidism and each one independently worsens shedding; blood testing should precede any supplementation protocol.
- A personalized formula calibrated to your labs will always outperform a general hair-support product, because the root cause varies substantially from person to person in this population.
---
This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any supplement protocol, particularly if you are being treated for thyroid disease or managing hormone-related conditions.